Stockreport

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update [Yahoo! Finance]

Intensity Therapeutics, Inc.  (INTS) 
PDF each patient receives two doses of INT230-6 eight days apart, followed by the standard of care immunochemotherapy ("SOC") Safety looks favorable in Cohort A Some INT [Read more]